Oncology at AstraZeneca: The journey to the top

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

AstraZeneca’s rise in oncology may turn out to be one of the industry’s big all-time turnaround stories. BioCentury sat down with one of its architects, Susan Galbraith, to discuss the factors behind the pharma’s growth in oncology, and where she sees cancer medicine headed from here...